Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Supportive and palliative care

3827 - Automated Survival Prediction in Metastatic Cancer Patients Using High-Dimensional Electronic Medical Record Data


21 Oct 2018


Proffered paper session - Supportive and palliative care


End-of-Life Care

Tumour Site


Michael Gensheimer


Annals of Oncology (2018) 29 (suppl_8): viii548-viii556. 10.1093/annonc/mdy295


M.F. Gensheimer1, A.S. Henry2, D.J. Wood2, T.J. Hastie2, S. Aggarwal1, S. Dudley1, P. Pradhan1, I. Banerjee2, E. Cho3, K. Ramchandran4, E. Pollom1, A. Koong1, D. Rubin2, D.T. Chang1

Author affiliations

  • 1 Radiation oncology, Stanford University School of Medicine, 94305 - Stanford/US
  • 2 Biomedical Data Science, Stanford University School of Medicine, 94305 - Stanford/US
  • 3 Genentech, Genentech, 94080 - South San Francisco/US
  • 4 Oncology, Stanford University School of Medicine, 94305 - Stanford/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3827


Oncologists use patients’ life expectancy to guide medical decisions and may benefit from a tool that provides accurate, unbiased assessments of prognosis. Existing prognostic models generally use only a few predictor variables. We used a large electronic medical record dataset to train a prognostic model for patients with metastatic cancer.


The model was trained and tested using data from 12,588 patients treated for metastatic cancer in the Stanford Health Care system from 2008-2017. Data sources included provider note text, labs, vital signs, procedures, medication orders, and diagnosis codes. Patients were divided randomly into training and test sets (80%/20% split). A regularized Cox proportional hazards model with 4,126 predictor variables was fit to the training set and evaluated on the test set. A landmarking approach was used due to the multiple observations per patient, with t0 set to the time of metastatic cancer diagnosis. Performance was also evaluated using 399 palliative radiation courses in test set patients. An existing published model that uses performance status, primary tumor site, and treated site was used as a baseline [Chow, JCO 2008:20;26(36)].


From the first visit after metastatic cancer diagnosis, median follow-up was 14.5 months and median overall survival was 20.9 months. Patients were seen for 384,402 daily visits. The prognostic model’s C-index for overall survival was 0.79 in the test set (averaged across landmark times). For palliative radiation courses, the C-index was 0.75 (95% CI 0.72-0.78), compared to 0.64 (95% CI 0.60-0.67) for an existing published model (p < 0.001).Table: 1512O

Predicted vs actual survival for 2,518 test set patients at landmark time t0 (first visit after diagnosis of metastatic cancer)

Predicted median survival in monthsActual median survival in months (95% CI)
0-3 (n = 106)1.3 (0.9-2.0)
3.1-6 (n = 172)3.7 (2.5-5.2)
6.1-12 (n = 382)6.7 (5.6-7.9)
>12 (n = 1858)35.7 (31.8-39.1)


The model showed high predictive performance, which was significantly better than that of an existing model. Because it is fully automated, the model can be used to examine providers’ practice patterns and could deployed in a decision support tool to help improve quality of care.

Clinical trial identification

Legal entity responsible for the study

Michael Gensheimer.


National Institutes of Health.

Editorial Acknowledgement


M.F. Gensheimer: Research funding: Varian Medical Systems, Philips Healthcare. E. Cho: Employee of Genentech. D. Rubin: Research funding: Philips Healthcare. D.T. Chang: Research funding, honoraria: Varian Medical Systems; Stock ownership: ViewRay. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.